CAMBRIDGE, Mass., Dec. 18, 2023 (GLOBE NEWSWIRE) Cullinan Oncology, Inc. (NASDAQ:CGEM) ("Cullinan Oncology") a biopharmaceutical company focused on modality-agnostic targeted oncology therapies, today announced
CAMBRIDGE, Mass., Dec. 18, 2023 Cullinan Oncology, Inc. a biopharmaceutical company focused on modality-agnostic targeted oncology therapies, today announced that Chief Executive Officer,.
Cullinan Oncology to Present at the 42nd Annual J.P. Morgan Healthcare Conference tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.
Cullinan Oncology Announces First Patient Dosed In Phase 1 Trial Evaluating CLN-617, A Novel Fusion Protein Uniquely Harnessing Both IL-2 And IL-12 Cy... menafn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from menafn.com Daily Mail and Mail on Sunday newspapers.
Cullinan Oncology, Inc. (NASDAQ:CGEM – Get Free Report) CFO Jeffrey Trigilio sold 1,926 shares of the stock in a transaction that occurred on Tuesday, December 12th. The shares were sold at an average price of $7.81, for a total value of $15,042.06. Following the sale, the chief financial officer now owns 86,237 shares of the […]